Blair William & Co. IL Reduces Thermo Fisher Scientific Holdings

Blair William & Co. IL has reduced its investment in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% during the fourth quarter, according to their latest Form 13F filing with the SEC. After selling 1,547 shares, the institutional investor now holds a total of 144,866 shares in the company, valued at approximately $75,364,000 based on their most recent filings.

Other Institutional Investments

In addition to Blair William & Co., several other hedge funds and institutional investors have adjusted their stakes in Thermo Fisher. Geode Capital Management LLC increased its ownership by 1.7% in the third quarter, acquiring an additional 127,564 shares for a total of 7,659,943 shares, worth $4,719,477,000. Coldstream Capital Management Inc. also raised its position by 11.4%, bringing its total to 9,705 shares valued at $5,972,000. Similarly, Greenwood Gearhart Inc. boosted its stake by 9.8%, now holding 20,579 shares worth $12,730,000. Nordea Investment Management AB expanded its holdings by 23.6% in the fourth quarter, owning 55,452 shares valued at $28,868,000 after buying 10,606 additional shares. Lastly, S.E.E.D. Planning Group LLC increased its position by 6.2%, now possessing 10,626 shares worth $5,528,000. Overall, institutional investors control about 89.23% of Thermo Fisher's stock.

Performance of Thermo Fisher Scientific Stock

As of Thursday, TMO shares opened at $513.40. The company exhibits a quick ratio of 1.29, a current ratio of 1.66, and a debt-to-equity ratio of 0.59. Its fifty-day and 200-day moving averages stand at $543.80 and $553.93, respectively. With a market capitalization of $193.68 billion, its price-to-earnings ratio is 31.06, and the PEG ratio is 2.99. The stock's 52-week range has seen a low of $493.30 and a high of $627.88.

Dividends and Earnings Reports

Thermo Fisher Scientific recently announced an increase in its quarterly dividend from $0.39 to $0.43, to be paid on April 15. Shareholders recorded by March 14 will benefit from this dividend, marking an annualized payout of $1.72, with a yield of 0.34%. The company's payout ratio is currently at 10.41%.

In the company’s last earnings report on January 30, it reported earnings of $6.10 per share, surpassing analysts' expectations of $5.94. The return on equity stood at 17.51%, with a net margin of 14.78%. Analysts anticipate Thermo Fisher Scientific will achieve 23.28 earnings per share this year.

Analysts' Predictions and Ratings

Recent updates from equity analysts have generally provided optimistic outlooks for Thermo Fisher. Morgan Stanley raised its price target from $647.00 to $678.00, maintaining an "overweight" rating. Similarly, Royal Bank of Canada set a target of $693.00, while Wells Fargo increased their objective from $660.00 to $680.00, also assigning an "overweight" rating. UBS Group further raised its target from $700.00 to $715.00, confirming a "buy" rating. However, Bank of America reduced its price objective from $675.00 to $660.00, maintaining a "buy" stance. The market consensus shows an overall rating of "Moderate Buy" with a price target averaging around $653.23.

Insider Trading Activity

Recent insider trading has seen SVP Michael A. Boxer sell 3,775 shares at an average price of $532.52, totaling $2,010,263. Following this sale, he holds 10,816 shares, representing a 25.87% decrease in his ownership. CFO Stephen Williamson also sold 9,825 shares at an average price of $585.59, amounting to $5,753,421.75. Post-sale, he owns 27,296 shares, reflecting a 26.47% reduction. Over the past 90 days, insiders sold 23,900 shares worth a total of $13,106,062, with insiders currently holding about 0.34% of the stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is a prominent player in providing life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharmaceutical services across North America, Europe, Asia-Pacific, and globally. Its Life Sciences Solutions segment focuses on reagents, instruments, and consumables essential for biological and medical research, drug and vaccine production, as well as disease diagnosis, serving various markets including pharmaceutical and biotechnology sectors.

investment, shares, dividends